Anti-HLA-DQ antibodies are highly and independently related to the C1q-binding capacity of HLA antibodies

被引:4
作者
Arreola-Guerra, Jose M. [1 ]
Morales-Buenrostro, Luis E. [2 ]
Granados, Julio [1 ]
Castelan, Natalia [3 ]
de Santiago, Adrian [3 ]
Arvizu, Adriana [3 ]
Gonzalez-Tableros, Norma [3 ]
Lopez, Mayra [3 ]
Vilatoba, Mario [1 ]
Albertu, Josefina [1 ]
机构
[1] Natl Inst Med Sci & Nutr Salvador Zubiran, Dept Transplantat, Vasco Quiroga 15,Secc 16, Mexico City 14080, DF, Mexico
[2] Natl Inst Med Sci & Nutr Salvador Zubiran, Dept Nephrol Mineral Metab, Vasco Quiroga 15,Secc XVI, Mexico City 14080, DF, Mexico
[3] Natl Inst Med Sci & Nutr Salvador Zubiran, Histocompatibil Lab, Vasco Quiroga 15,Secc 16, Mexico City 14080, DF, Mexico
关键词
DONOR-SPECIFIC ANTIBODIES; C1Q ASSAY; COMPLEMENT-BINDING; MEDIATED REJECTION; CLINICAL-RELEVANCE; RISK; TRANSPLANTATION; STRENGTH; TITER;
D O I
10.1016/j.trim.2017.02.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The complement-binding capacity of anti-HLA antibodies (HLAabs) is recognized as a key pathogenic factor. The aim of this study is to describe the patient characteristics associated to the presence of C1q+ as well as those of the Abs per se when associated to C1q binding. Methodology: This is a cross-sectional, observational, descriptive study of patients with previous sensitizing factors and awaiting a kidney transplant (KT). We determined anti-HLA antibodies and their C1q binding capacity with the C1q assay. Results: Among the 55 included patients, 26 (47.2%) had at least one C1q + anti-HLAab. A previous transplant history, a greater number of HLAabs, a greater % of class I or class II PRA, the average MR of all HLAabs, the MR of the dominant HLAab and the HLAab antigenic specificities against HLA-B,-C and-DQ all proved to be risk factors associated to the presence of Cl q binding HLAabs (Clq +). In the total population, were detected 1268 HLAabs, 230 (18.1%) of which were Cl q +. On multivariate analysis, both HLAabs against the HLA-DQantigenic specificity (OR 9.82 95% CI 5.4-17.6, p < 0.001) and the MR documented by LABScreen (R) SAB (OR 12% Cl 1.22-1.3, p < 0.001), proved to be risk factors. Conclusion: Anti-HLA-DQ antibodies and the MFI (LABScreen (R) SAB) are highly and independently related to the C1q-binding capacity of HLA antibodies. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:10 / 16
页数:7
相关论文
共 35 条
[1]  
Arreola-Guerra J. M., 2016, J TRANSP SECUR, V2016
[2]   Probability of deceased donor kidney transplantation based on % PRA [J].
Bostock, I. C. ;
Alberu, J. ;
Arvizu, A. ;
Hernandez-Mendez, E. A. ;
De-Santiago, A. ;
Gonzalez-Tableros, N. ;
Lopez, M. ;
Castelan, N. ;
Contreras, A. G. ;
Morales-Buenrostro, L. E. ;
Gabilondo, B. ;
Vilatoba, M. .
TRANSPLANT IMMUNOLOGY, 2013, 28 (04) :154-158
[3]   Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads [J].
Chen, G. ;
Sequeira, F. ;
Tyan, D. B. .
HUMAN IMMUNOLOGY, 2011, 72 (10) :849-858
[4]  
Chen G., 2013, ABSTRACTS HUMAN IMMU, V74, P1
[5]   Clinical relevance of pretransplant anti-HLA donor-specific antibodies: Does C1q-fixation matter? [J].
Crespo, Marta ;
Torio, Alberto ;
Mas, Virginia ;
Redondo, Dolores ;
Perez-Saez, Maria J. ;
Mir, Marisa ;
Faura, Anna ;
Guerra, Rita ;
Montes-Ares, Olga ;
Checa, Maria D. ;
Pascual, Julio .
TRANSPLANT IMMUNOLOGY, 2013, 29 (1-4) :28-33
[6]   Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies [J].
Croze, Laure-Emmanuelle ;
Tetaz, Rachel ;
Roustit, Matthieu ;
Malvezzi, Paolo ;
Janbon, Benedicte ;
Jouve, Thomas ;
Pinel, Nicole ;
Masson, Dominique ;
Quesada, Jean-Louis ;
Bayle, Francois ;
Zaoui, Philippe .
TRANSPLANT INTERNATIONAL, 2014, 27 (08) :775-783
[7]   Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation [J].
DeVos, Jennifer M. ;
Gaber, A. Osama ;
Knight, Richard J. ;
Land, Geoffrey A. ;
Suki, Wadi N. ;
Gaber, Lillian W. ;
Patel, Samir J. .
KIDNEY INTERNATIONAL, 2012, 82 (05) :598-604
[8]   Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes [J].
Duquesnoy, Rene J. ;
Awadalla, Yehia ;
Lomago, Jon ;
Jelinek, Larry ;
Howe, Judy ;
Zern, Dwayne ;
Hunter, Betty ;
Martell, Joan ;
Girnita, Alin ;
Zeevi, Adriana .
TRANSPLANT IMMUNOLOGY, 2008, 18 (04) :352-360
[9]   Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification [J].
Gibney, Eric M. ;
Cagle, Linda R. ;
Freed, Brian ;
Warnell, Stephanie E. ;
Chan, Larry ;
Wiseman, Alexander C. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (09) :2625-2629
[10]  
Hahn A. B., 2000, AM SOC HISTOCOMPATIB